0001209191-21-011322.txt : 20210217
0001209191-21-011322.hdr.sgml : 20210217
20210217165529
ACCESSION NUMBER: 0001209191-21-011322
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210217
DATE AS OF CHANGE: 20210217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wright-Mitchell Jane
CENTRAL INDEX KEY: 0001614568
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39323
FILM NUMBER: 21645718
MAIL ADDRESS:
STREET 1: C/0 ACELRX PHARMACEUTICALS, INC.
STREET 2: 351 GALVESTON DRIVE
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
FORMER NAME:
FORMER CONFORMED NAME: Mitchell Jane Wright
DATE OF NAME CHANGE: 20140723
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vaxcyte, Inc.
CENTRAL INDEX KEY: 0001649094
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 464233385
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 353 HATCH DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
BUSINESS PHONE: 650-837-0111
MAIL ADDRESS:
STREET 1: 353 HATCH DR
CITY: FOSTER CITY
STATE: CA
ZIP: 94404
FORMER COMPANY:
FORMER CONFORMED NAME: SutroVax, Inc.
DATE OF NAME CHANGE: 20150724
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-16
0
0001649094
Vaxcyte, Inc.
PCVX
0001614568
Wright-Mitchell Jane
C/O VAXCYTE, INC.
353 HATCH DRIVE
FOSTER CITY
CA
94404
0
1
0
0
General Counsel
Common Stock
2021-02-16
4
M
0
2500
2.03
A
4062
D
Common Stock
2021-02-16
4
S
0
2500
26.95
D
1562
D
Stock Option (right to buy)
2.03
2021-02-16
4
M
0
2500
0.00
D
2029-03-20
Common Stock
2500
202468
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported is a weighted-average price. The shares were sold at prices ranging from $26.52 to $27.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.
/s/ Winston Macaraeg, Attorney-in-Fact
2021-02-17